E-Mail Efficiency

E-Mail Efficiency Thank you for publishing Joshua Lederberg's detailed descriptions of his attempts to cope with the literature (The Scientist, Feb. 8, 1993, page 10). I would like to make an additional comment about Internet use. The volume not only of publications but also of grant applications is expanding explosively. I manage the radiation study section (RAD) at the National Institutes of Health, Division of Research Grants. We meet formally three times per year. February 8-10 we rece

Written byPaul Strudler
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Thank you for publishing Joshua Lederberg's detailed descriptions of his attempts to cope with the literature (The Scientist, Feb. 8, 1993, page 10).

I would like to make an additional comment about Internet use. The volume not only of publications but also of grant applications is expanding explosively.

I manage the radiation study section (RAD) at the National Institutes of Health, Division of Research Grants. We meet formally three times per year. February 8-10 we received 97 applications, a real strain for roughly 20 reviewers in three days. It is also a strain on my personal resources to ensure that all facets of the applications are appropriate (proper paperwork for human and animal subjects, budgets, curriculum vita, supplementary data).

This year, in the revised PHS 398 (Public Health Service grant application form) there is a box on the front page for Internet/Bitnet addresses of the applicants. Of the 97 applicants ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies